专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003080646A3 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON 审中-公开
公开(公告)号：WO2003080646A3
公开(公告)日：2003-10-02
申请号：PCT/US2003/006679
申请日：2003-03-04
申请人： MEDICAL COLLEGE OF OHIO , THE UNIVERSITY OF TOLEDO , SWIERCZ, Rafal , SELMAN, Steven, H. , JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , CHOROSTOWSKA-WYNIMKO, Joanna
发明人： SWIERCZ, Rafal , SELMAN, Steven, H. , JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , CHOROSTOWSKA-WYNIMKO, Joanna
IPC分类号： C07K14/00
摘要： The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfliydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyerfibrinolysis, hemophilia, and vessel leakage syndrome.

2. 发明申请

WO2009014564A9 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 MOLECULE AND METHODS BASED THEREON 审中-公开
公开(公告)号：WO2009014564A9
公开(公告)日：2009-01-29
申请号：PCT/US2008/005272
申请日：2008-04-24
申请人： THE UNIVERSITY OF TOLEDO , JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , SELMAN, Steven, H.
发明人： JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , SELMAN, Steven, H.
IPC分类号： A61K38/55
摘要： The present invention relates to a modified plasminogen activator inhibitor type- 1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI- 1, but is deficient in one or more functional activities as compared to the wild-type PAI- 1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following funtional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-I molecules and methods of using these pharmaceutical compositions for treatment.

3. 发明申请

WO2009045412A3 METHODS OF TREATMENT USING MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 MOLECULES 审中-公开
公开(公告)号：WO2009045412A3
公开(公告)日：2009-04-09
申请号：PCT/US2008/011330
申请日：2008-10-01
申请人： AMERICAN DIAGNOSTICA, INC. , THE UNIVERSITY OF TOLEDO , JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , SELMAN, Steven, H. , GREENFIELD, Robert, S.
发明人： JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , SELMAN, Steven, H. , GREENFIELD, Robert, S.
IPC分类号： A61K38/57 , A61K38/48 , A61P7/04
摘要： The present invention generally relates to methods of treating bleeding diseases and disorders and to promote wound healing. The methods comprises administering a procoagulant, preferably factor VII a, and a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of the PAI-1 molecule. The invention also relates to methods of treating respiratory diseases using a modified PAI-1 molecule.

4. 发明申请

WO2003080646A2 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON 审中-公开
标题翻译：改良的PLASMINOGEN激活剂抑制剂类型1及其方法
公开(公告)号：WO2003080646A2
公开(公告)日：2003-10-02
申请号：PCT/US2003/006679
申请日：2003-03-04
申请人： MEDICAL COLLEGE OF OHIO , SWIERCZ, Rafal , SELMAN, Steven, H. , JANKUN, Jerzy
发明人： SWIERCZ, Rafal , SELMAN, Steven, H. , JANKUN, Jerzy
IPC分类号： C07K
CPC分类号： C07K14/8132 , A61K38/00
摘要： The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfliydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyerfibrinolysis, hemophilia, and vessel leakage syndrome.
摘要翻译：本发明基于以下发现：其中两个或更多个不含磺酰基基团的氨基酸残基已经被含有巯基的氨基酸残基替代的修饰的纤溶酶原激活物抑制剂I型（PAI-1）因此，形成分子内二硫键，体内半衰期有所增加。还公开了修饰的PAI-1蛋白，其衍生物和类似物，特异性抗体，核酸分子和宿主细胞。还提供了生产改性PAI-1，衍生物和类似物的方法。本发明还涉及使用该组合物进行治疗的治疗剂，药物组合物和方法。本发明可以用于抑制受试者的血管生成，从而治疗与不期望的血管生成和细胞增殖相关的疾病或病症。这些病症包括牛皮癣，慢性炎症，肿瘤浸润和转移以及血管发生是致病性的病症。本发明的修饰的PAI-1分子可用于治疗，预防，治疗和改善心血管疾病，例如但不限于与血纤维蛋白溶解，血友病和血管渗漏综合征相关的那些。

5. 发明公开

EP1487867A2 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON 有权
标题翻译：改性型纤溶酶原和基于事实的过程
公开(公告)号：EP1487867A2
公开(公告)日：2004-12-22
申请号：EP03745086.3
申请日：2003-03-04
申请人： MEDICAL COLLEGE OF OHIO , THE UNIVERSITY OF TOLEDO
发明人： SWIERCZ, Rafal , SELMAN, Steven, H. , JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , CHOROSTOWSKA-WYNIMKO, Joanna
IPC分类号： C07K14/00 , C07H1/04 , A61K38/00
CPC分类号： C07K14/8132 , A61K38/00
摘要： The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfliydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyerfibrinolysis, hemophilia, and vessel leakage syndrome.

6. 发明授权

EP1487867B1 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON 有权
标题翻译：改性型纤溶酶原和基于事实的过程
公开(公告)号：EP1487867B1
公开(公告)日：2009-01-21
申请号：EP03745086.3
申请日：2003-03-04
申请人： MEDICAL COLLEGE OF OHIO , The University of Toledo
发明人： SWIERCZ, Rafal , SELMAN, Steven, H. , JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , CHOROSTOWSKA-WYNIMKO, Joanna
IPC分类号： C07K14/00 , C07H1/04 , A61K38/00
CPC分类号： C07K14/8132 , A61K38/00
摘要： The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfliydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyerfibrinolysis, hemophilia, and vessel leakage syndrome.

7. 发明申请

WO1993024141A1 DELIVERY OF A CYTOTOXIC COMPOUND TO A CANCER CELL USING A PATHWAY OF PLASMINOGEN ACTIVATOR MATERIAL 审中-公开
标题翻译：将细胞毒素化合物递送至使用PLASMINOGEN ACTIVATOR材料途径的癌细胞
公开(公告)号：WO1993024141A1
公开(公告)日：1993-12-09
申请号：PCT/US1993005034
申请日：1993-05-27
申请人： THE UNIVERSITY OF TOLEDO
发明人： THE UNIVERSITY OF TOLEDO , JANKUN, Jerzy , HART, Richard
IPC分类号： A61K37/36
CPC分类号： C07K14/81 , A61K47/62
摘要： A method of delivering a cytotoxic compound to a cancer cell and getting the compound inside the cancer cell using a plasminogen material such as a plasminogen activator inhibitor (PAI-1). The toxic compound is coupled to PAI-1 to form a reaction product that is coupled with urokinase plasminogen activator (uPA) that is bound to the cell surface by uPA receptors (uPAR). The resultant complex is internalized to enter the cancer cell to deliver the cytotxic compound within the cell.
摘要翻译：使用纤溶酶原物质如纤溶酶原激活物抑制剂（PAI-1）将细胞毒性化合物递送至癌细胞并使化合物进入癌细胞内的方法。有毒化合物与PAI-1偶联以形成与uPA受体（uPAR）结合于细胞表面的尿激酶纤溶酶原激活物（uPA）结合的反应产物。所得的复合物被内化以进入癌细胞以将细胞毒化合物递送到细胞内。

8. 发明公开

EP2150273A2 MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 MOLECULE AND METHODS BASED THEREON 审中-公开
标题翻译：修饰的疟原虫激活抑制剂1型分子及其基于方法
公开(公告)号：EP2150273A2
公开(公告)日：2010-02-10
申请号：EP08826564.0
申请日：2008-04-24
申请人： The University of Toledo
发明人： JANKUN, Jerzy , SKRZYPCZAK-JANKUN, Ewa , SELMAN, Steven, H.
IPC分类号： A61K38/55
CPC分类号： C07K14/8132 , A61K38/00
摘要： The present invention relates to a modified plasminogen activator inhibitor type- 1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI- 1, but is deficient in one or more functional activities as compared to the wild-type PAI- 1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following funtional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-I molecules and methods of using these pharmaceutical compositions for treatment.
摘要翻译：本发明涉及显示PAI-1的活性形式的增加的体内半衰期但与一种或多种功能活性相比缺乏一种或多种功能活性的修饰的纤溶酶原激活物抑制剂-1型（PAI-1）分子野生型PAI-1蛋白。表现出增加的半衰期的改性PAI-1分子进一步显示至少一种以下功能特征：（i）与至少一种以下分子的结合活性降低：尿激酶纤溶酶原激活物（uPA），组织纤溶酶原激活物（ tPA）和玻连蛋白（Vn）; 和（ii）针对至少一种以下分子的特异性活性降低：uPA，tPA和Vn。本发明还涉及包含修饰的PAI-1分子的药物组合物以及使用这些药物组合物进行治疗的方法。

9. 发明公开

EP0643584A1 DELIVERY OF A CYTOTOXIC COMPOUND TO A CANCER CELL USING A PATHWAY OF PLASMINOGEN ACTIVATOR MATERIAL 失效
标题翻译：细胞毒性化合物通过致敏激活物质途径递送至癌细胞
公开(公告)号：EP0643584A1
公开(公告)日：1995-03-22
申请号：EP93914191.0
申请日：1993-05-27
申请人： THE UNIVERSITY OF TOLEDO
发明人： JANKUN, Jerzy , HART, Richard
IPC分类号： A61K47 , C07K14
CPC分类号： C07K14/81 , A61K47/62
摘要： A method of delivering a cytotoxic compound to a cancer cell and getting the compound inside the cancer cell using a plasminogen material such as a plasminogen activator inhibitor (PAI-1). The toxic compound is coupled to PAI-1 to form a reaction product that is coupled with urokinase plasminogen activator (uPA) that is bound to the cell surface by uPA receptors (uPAR). The resultant complex is internalized to enter the cancer cell to deliver the cytotxic compound within the cell.
摘要翻译：将细胞毒性化合物递送至癌细胞并使用纤溶酶原物质如纤溶酶原激活物抑制剂（PAI-1）将化合物置于癌细胞内的方法。毒性化合物与PAI-1偶联以形成与uPA受体（uPAR）与细胞表面结合的尿激酶纤溶酶原激活物（uPA）偶联的反应产物。所得的复合物被内化以进入癌细胞以在细胞内递送细胞毒化合物。

10. 发明授权

EP0643584B1 DELIVERY OF A CYTOTOXIC COMPOUND TO A CANCER CELL USING A PATHWAY OF PLASMINOGEN ACTIVATOR MATERIAL 失效
标题翻译： GIVING癌细胞细胞毒性化合物使用PLASMINOGENAKTIVATORMATERIAL的路径
公开(公告)号：EP0643584B1
公开(公告)日：2000-03-15
申请号：EP93914191.7
申请日：1993-05-27
申请人： THE UNIVERSITY OF TOLEDO
发明人： JANKUN, Jerzy , HART, Richard
IPC分类号： A61K38/49 , C07K14/00
CPC分类号： C07K14/81 , A61K47/62
摘要： A method of delivering a cytotoxic compound to a cancer cell and getting the compound inside the cancer cell using a plasminogen material such as a plasminogen activator inhibitor (PAI-1). The toxic compound is coupled to PAI-1 to form a reaction product that is coupled with urokinase plasminogen activator (uPA) that is bound to the cell surface by uPA receptors (uPAR). The resultant complex is internalized to enter the cancer cell to deliver the cytotxic compound within the cell.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式